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ABSTRACT 
A simple and efficient NP-HPLC UVD method was developed and validated for the quantitative determination of Orlistat SSRR Impurity in Orlistat dosage 
forms. An isocratic separation was achieved by using a Chiral Pack IA, 250 mm × 4.6 mm, 5 µm particle size column with a flow rate of 1.0 ml/min and using 
a UV detector at 205 nm. The mobile phase consists of n-Hexane and Isopropyl alcohol (70:30, v/v). The drug was subjected oxidation, hydrolysis, photolysis 
and heat to apply stress conditions. Complete separation was achieved for the parent compound and SSRR Isomer of Orlistat in an overall analytical run time 
of approximately 45 min with the parent compound Orlistat eluting at approximately at 5 min. The method was linear over the concentration range of 3.1 - 40 
µg/ml with a limit of detection and limit of quantification 1.0 µg/ml and 3.1µg/ml respectively. The method has been the requisite accuracy, selectivity, 
sensitivity and precision. Degradation products resulting from the stress studies did not interfere with the detection of Orlistat and SSRR Impurity and the test 
method is thus stability-indicating. 
KEYWORDS: Normal phase, Column temperature, SSRR of Orlistat, Development & validation. 
 
INTRODUCTION 
Orlistat, N-formyl-l-leucine (1S)-1-[[(2S, 3S)-3-hexyl-4-oxo-
2-oxetanyl] methyl] dodecyl ester (Fig. 1)
1 is a novel, non-
systemically  absorbed,  antiobesity  agent  which  selectively 
inhibits  the  absorption  of  approximately  30%  of  fatty 
components  from  the  diet
2.Orlistat  is  a  semisynthetic 
hydrogenated  derivative  of  a  naturally  occurring  lipase 
inhibitor  produced  by  Streptomyces  toxytricini
3-4  and  is  a 
potent  inhibitor  of  gastric,  pancreatic
5  and  carboxylester 
lipases both in vitro and in vivo
6. This agent reduced weight 
in  obese  adults  and  adolescents  with  or  without  co-
morbidities  such  as  type  2  diabetes  mellitus, 
hypercholesterolemia, hypertension and metabolic syndrome. 
SSRR Isomer impurity (Fig. 2) is one of the process related 
chiral isomer of Orlistat and it was formed from SRR isomer 
of Oxetanone during manufacturing process of Orlistat.  
There  is  a  dearth  of  analytical  methods  reported  in  the 
literature
7-12  but  no  method  has  been  reported  for  the 
determination  of  Orlistat  SSRR  Impurity  by  using  HPLC 
with UV detection. The vendor was developed HPLC with 
ELSD detector method for the estimation of SSRR Impurity 
of Orlistat.  
The  objective  of  this  work  is  to  develop  and  validate  a 
simple,  precise  and  accurate  HPLC  method  with  UV 
detection and it should be stability indicating. The developed 
normal  phase  high  performance  liquid  chromatographic 
technique  equipped  with  UV  detector  method
13-14  was 
validated  according to  ICH  guidelines
15 and  found  to  be  a 
simple, precise, specific, linear, accurate rugged and robust 
and stability Indicating method. 
EXPERIMENTAL 
Materials and Chemicals 
SSRR isomer of Orlistat is a process related impurity which 
is  obtained  from  Ranbaxy  Laboratories.  Isopropyl  alcohol 
and n-Hexane (Merck India Limited) of  HPLC grade were 
used  for  mobile  phase  preparation  and  for  sample 
preparation. 
 
Equipments 
The analysis was carried out in Agilent HPLC equipped with 
UV  detector  and  Agilent  HPLC  with  PDA  Detector.  Data 
acquisition was carried out by using Empower Software. 
Chromatographic conditions 
The separation of Orlistat and SSRR isomer impurity were 
achieved by using a mobile phase of a mixture of n-Hexane 
and Isopropyl alcohol in the ratio of 70:30, v/v respectively. 
The chromatographic separation was achieved in the normal 
phase  mode.  The  high  performance  liquid  chromatography 
equipped with UV detector at 205 nm and by using a Chiral 
Pack IA, 250 mm × 4.6 mm, 5 µm particle size column with 
a 1.0 ml/min flow rate, 10 µl of injection volume and 10 °C 
of column heater temperature. The separation was achieved 
within  the  45  min  for  the  Orlistat  and  SSRR  Isomer  of 
Orlistat, the retention time of the both peaks were 5.4 and 
13.0  respectively.  The  detection  and  peak  purity 
establishment  of  active  and  SSRR  impurity  were  achieved 
using photo diode array (PDA) detector.  
Diluted standard preparation 
A  standard  stock  solution  of  Orlistat  (1000  μg/ml)  was 
prepared  by  using  the  diluent  (mobile  phase).  The  final 
concentration of diluted standard was 20 µg/ml.  
Sample preparation 
An aliquot  of  powder  equivalent to  the  weight  of  100  mg 
Orlistat was accurately weighed into a 10 ml volumetric flask 
and made up to volume with diluent to yield concentration of 
10 mg/ml.  
RESULTS AND DISCUSSION 
The analytical test method of related substances plays a major 
role in pharmaceutical solid dosage forms for quantification 
of  impurities  which  are  present  in  the  dosage  forms.  The 
main  aim  of  this  study  is  to  get  the  separation  of  SSRR 
Impurity  of  Orlistat  from  the  main  analyte  without 
interference.  Different  mobile  phases  in  different  ratios  of 
Isopropyl alcohol and n-Hexane were tried for separation of 
SSRR  impurity  from  main  analyte.  The  chromatographic 
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using single mobile phase consist of a mixture of n-Hexane 
and  Isopropyl  alcohol  in  the  ratio  70:30,  v/v  respectively.  
The resolution in between SSRR impurity and Orlistat peaks 
found  more  in  developed  isocratic  method.  The  typical 
retention  times  of  Orlistat and  SSRR  Impurity  are  5.4  and 
13.1 minutes respectively.  The SSRR impurity pertaining to 
active moiety is estimated at specific wavelength of 205 nm. 
The developed HPLC method was validated and found to be 
specific, precise and accurate and also stability indicating for 
the  estimation  of  SSRR  Impurity  in  Orlistat  capsules 
formulation.  A  typical  chromatogram  of  diluent,  diluted 
standard and SSRR impurity spiked sample was shown in the 
Fig.3-5. 
Optimization of test method 
The test method chromatographic conditions were optimized  
by  using  a  Chiral  Pack  IA,  250  ×  4.6  mm,  5  µm  with  a 
mobile  phase  containing  a  mixture  of  n-Hexane  and 
Isopropyl  alcohol  in  the  ratio  70:30,  v/v  respectively.  The 
column temperature was maintained at 10 °C with a flow rate 
of  1.0  ml/min.  The  Retention  time  of  Orlistat  and  SSRR 
isomer  of  Orlistat  were  found  to  be  5.4  and  13.1  minutes 
respectively.  The  Relative  retention  time  of  Orlistat  SSRR 
isomer was found to be 2.42 with respect to the main analyte 
peak. The developed test method is capable to separate SSRR 
impurity  from  main  analyte  with  a  good  resolution.  The 
tailing factor for both peaks and resolution were found to be 
1.0  and  not  less  than  3.0  respectively.  The  peak  purity  of 
main  analyte  and  SSRR  impurity  were  found  within  the 
limits and no purity flag was observed in purity results table 
of Empower software.  
Extraction procedure for Orlistat and SSRR impurity 
The  extraction  of  Orlistat  and  SSRR  impurity  from 
pharmaceutical  formulations  in  capsule  form  as  achieved 
through the selective extraction of the active ingredient with 
n-Hexane  and  Isopropyl  alcohol  in  the  ratio  of  70:30,  v/v 
respectively.  The  finished  product  containing  volumetric 
flasks were sonicated in Ultra Sonic power sonicator for 5 
min  to  extract  the  drug  moiety  from  the  pharmaceutical 
formulations.  Suitable  aliquots  of  solution  were  filtered 
through a 0.45 μm Nylon filter and used as a test. 
Establishment  of  Relative  Response  Factor  for  Orlistat 
SSRR impurity 
Prepared  and  injected  a  series  of  solutions  consisting  of 
SSRR Impurity and Orlistat in the range of 0.10% to 0.30% 
(0.1%, 0.15%, 0.2%.0.25%, 0.3%) levels. The load of 10 µl 
injection  volume  of  sample  was  injected  into  the  liquid 
chromatograph and calculated the Relative Response Factor 
(RRF)  of  SSRR  Impurity  with respect to  Orlistat  from  the 
calibration curve data. The RRF value of SSRR was found to 
be  0.96.  The  Relative  Retention  Time  (RRT)  of  SSRR 
Impurity was found to be 2.42. 
VALIDATION 
System suitability 
The system suitability parameters were evaluated by making 
the injection of test sample spiked with SSRR impurity. The 
system is deemed to be suitable as the tailing factor ≤ 1.5 and 
the resolution between Orlistat and SSRR impurity is >3.0. 
Specificity 
In  order  to  determine  whether  the  developed  analytical 
method was stability-indicating, Orlistat capsules and Orlistat 
active  pharmaceutical ingredient  (API)  were  stressed  under 
various conditions to conduct forced degradation studies. As 
Orlistat is  practically  insoluble  in  water  and is  very  easily 
soluble in diluent. 
The specificity  was examined by analyzing a solution of  a 
placebo, which consisted of all the excipients and capsules 
shell without the drug substance as per ICH guidelines (ICH, 
Q2B).  The  degradation  was  observed  for  Orlistat  during 
stress  conditions  like  UV  light,  Sunlight,  Heat,  Water  and 
also  acidic,  basic,  Oxidation,  Hydrolysis  and  Humidity 
conditions. The acidic, basic, and oxidation stress conditions 
studies were carried out by refluxing API for 6hours with 1N 
HCl, 1N NaOH and 3% Hydrogen peroxide respectively. The 
thermal  degradation  was  carried  out  by  heating  the  drug 
product at 40°C for 24hours and the photo degradation was 
performed exposing the drug product to 1.2 million lux hours 
and 200 watt hours/m
2 in photo stability chambers. All the 
stress conditions and purity angle and purity threshold values 
are reported in Table.1 and Fig.6. 
Precision  
The precision of test method was evaluated by analyzing six 
samples  of  Orlistat  by  spiking  SSRR  impurity  at  target 
concentration  level  (i.e.  0.2%)  with  respect  to  test 
concentration.  The  %R.S.D  of  SSRR  impurity  from  six 
sample preparations were found to be 1.0 which indicates that 
precision  of  the  method  was  precise  for  quantification  of 
SSRR impurity (Tab.2). 
Linearity 
Linearity of ‘SSRR impurity of Orlistat’ was conducted from 
LOQ  level  to  200%  of  the  target  concentration  (i.e. 
0.2%).The linearity graph was plotted for “SSRR impurity of 
Orlistat’  in  between  concentration  versus  detector response 
(area).  The  correlation  coefficient  was  found  to  be  0.998. 
Linearity plot is shown in Fig.7.   
Accuracy 
The  % recovery  of  SSRR  impurity  of  Orlistat and  Orlistat 
were  determined  by  spiking  the  SSRR  impurity  of  Orlistat 
and main analyte at five different levels starting from 50% to 
150%  of  the  target  concentration  level  (i.e.  0.2%)  of  the 
impurity. The % recovery of impurity and main analyte were 
found within the limits as per ICH guidelines (Tab.3). 
LIMIT  OF  DETECTION  &  LIMIT  OF 
QUANTIFICATION 
LOD and LOQ Establishment 
A  series  of  different  concentrations  of  SSRR  of  Orlistat 
solutions were prepared in diluent. The limit of detection and 
limit of quantification were established by based on signal to 
noise ratio. The signal to noise ratio 3 for LOD and 10 for 
LOQ were found. The LOQ concentration was found to be 
0.028% for Orlistat SSRR impurity (Tab.4). 
Precision at LOQ Level 
The precision at limit of quantification level was determined 
by preparing six spiked solutions of Orlistat SSRR impurity 
at  LOQ  level.  The  %  RSD  for  the  impurity  from  six 
preparations  was  found  within  the  limits  as  per  ICH 
guidelines. 
Accuracy at LOQ Level 
Samples were prepared in triplicate by spiking with Orlistat 
isomer impurity (SSRR) at a concentration level of limit of 
quantification and injected into HPLC. The mean %recovery 
of  impurity  was  found  within  the  limits  as  per  ICH 
guidelines. 
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The  solution  stability  of  the  standard  and  impurity  were 
studied for about 2 days on bench top and in refrigerator. The Palakurthi Ashok Kumar et al. IRJP 2012, 3 (4) 
Page 352 
aged  solutions  were  injected  in  to  liquid  chromatograph 
against with freshly prepared standard solution; the samples 
were stable for a period of 2 days on bench top.  
Robustness 
The  robustness  was  investigated  by  varying  the  conditions 
with respect to change in the flow rate, column temperature 
and  IPA  composition  in  mobile  phase.  The  study  was 
conducted at different flow rates of 0.8ml/min and 1.2ml/min 
instead of 1.0ml/min to study the effect of the change in flow 
rate. The column temperature was adjusted to 5°C and 15°C 
instead of 10°C column oven temperature, to study the effect 
of  the  change  in  column  temperature.  Organic  phase 
composition (IPA) variation was studied 90% and 110% in 
mobile  phase,  to  study  the  effect  of  organic  phase 
composition  variation  in  mobile  phase.  The  method  was 
found  to  be  robust  with  respect  to  flow  rate,  column 
temperature  and  organic  phase  composition  without  any 
changes in system suitability parameters such as tailing factor 
and RRT of SSRR impurity (Tab.5). 
CONCLUSION 
The  simple,  selective,  isocratic  mode  normal  phase  high 
performance  liquid  chromatographic  method  provides 
selective  quantification  of  SSRR  impurity  without 
interference  of  blank,  placebo,  thereby  affirming  stability-
indicating  nature  of  the  method.  The  proposed  method  is 
highly  selective,  reproducible,  specific  and  rapid.  The 
developed  method  was  robust  in  the  separation  and 
quantification of Orlistat and SSRR Impurity. This developed 
method can be applied successfully for the quality control of 
commercial and routine analysis. The information presented 
herein  could  be  very  useful  for  quality  monitoring  of  bulk 
samples  and as  well  employed  to  check the quality  during 
stability studies. 
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Table 1: The results table of specificity of the method 
Sample No.  Stress Conditions  Purity angle  Purity threshold  Purity flag 
1  Acid stress  1.003  1.026  NO 
2  Base stress  0.228  1.036  NO 
3  Oxidation stress  0.509  1.017  NO 
4  Sunlight stress  0.612  1.028  NO 
5  UV light stress  0.675  1.026  NO 
6  Thermal stress  0.572  1.024  NO 
7  Humidity stress  0.574  1.028  NO 
8  Water stress  0.587  1.027  NO 
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Table 2: The results table of precision of the method 
Sample No. 
SSRR impurity 
RRT  % Imp (n) 
1  2.4  97.5 
2  2.4  99.0 
3  2.4  98.0 
4  2.4  97.5 
5  2.4  100.0 
6  2.4  98.0 
Average  2.4  98.5 
%RSD  0  1.0 
n=6 
 
Table 3: The results table of Accuracy of the method 
Sample No. 
Spike level 
(n)  ‘µg/ml’ added 
‘µg/ml’ found 
(recovered) 
Mean % 
recovery 
1  50%  10.222  9.533  93.3 
2  75%  15.333  14.867  97.0 
3  100%  20.444  18.500  90.5 
4  125%  25.555  23.200  90.8 
5  150%  30.666  28.967  94.5 
n=3 
         
Table 4: LOD and LOQ of SSRR Orlistat impurity 
Name of the Impurity 
Test Name 
Signal to Noise ratio  % Impurity at LOQ 
level  Conc. at Limit of 
Detection (µg/ml) 
Conc.at Limit of 
Quantification (µg/ml)  LOD  LOQ 
SSRR impurity  1.0  3.1  3.0  10.4  0.028 
 
 
Table 5: System suitability results from robustness 
Parameter 
Flow rate 
(ml/min) 
Column 
temperature (°C) 
Organic phase (IPA) variation 
(±10%) 
0.8  1.0  1.2  5  10  15  90  100  110 
Tailing factor for Orlistat 
peak  1.0  1.0  1.0  1.0  1.0  1.1  1.0  1.0  1.0 
RRT of SSRR impurity  2.50  2.40  2.48  2.78  2.40  2.24  2.61  2.40  2.48 
 
 
 
Figure 1: Chemical Structure of Orlistat 
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Figure 2: Chemical Structure of Orlistat SSRR Impurity 
 
 
Figure 3: A typical chromatogram of related substances blank 
 
Figure 4: A typical chromatogram of related substances diluted standard 
 
Figure 5: A typical chromatogram of related substances SSRR-impurity spiked sample Palakurthi Ashok Kumar et al. IRJP 2012, 3 (4) 
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Figure 6: Purity results chromatogram 
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Figure 7: Linearity plot for Orlistat SSRR Impurity 
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